These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20652780)

  • 21. Clinical pharmacology of trastuzumab.
    Levêque D; Gigou L; Bergerat JP
    Curr Clin Pharmacol; 2008 Jan; 3(1):51-5. PubMed ID: 18690878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab.
    Llinares-Tello F; de Salazar JR; Gallego JM; Soler GS; Ramírez CS; Heredia ES; García JM
    Clin Chem Lab Med; 2012 Oct; 50(10):1845-7. PubMed ID: 23089717
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
    Ternant D; Paintaud G
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic monoclonal antibody concentration monitoring: free or total?
    Kuang B; King L; Wang HF
    Bioanalysis; 2010 Jun; 2(6):1125-40. PubMed ID: 21083212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and considerations for development of therapeutic proteins in pediatric patients.
    Zhang Y; Wei X; Bajaj G; Barrett JS; Meibohm B; Joshi A; Gupta M
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S103-15. PubMed ID: 25707958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
    Stubenrauch K; Wessels U; Lenz H
    J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
    Mir O; Broutin S; Desnoyer A; Delahousse J; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():103-106. PubMed ID: 32089494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Precision Medicine in Clinical Trials in Inflammatory Bowel Disease.
    Khanna R; Vande Casteele N
    Inflamm Bowel Dis; 2019 Jan; 25(2):213-216. PubMed ID: 30256949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
    Lansita JA; Mounho-Zamora B
    Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.
    Gottlieb AB; Krueger JG; Sandberg Lundblad M; Göthberg M; Skolnick BE
    PLoS One; 2015; 10(8):e0134703. PubMed ID: 26252485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of monoclonal antibodies for the treatment of colorectal cancer.
    Goodin S
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S3-7; quiz S22-4. PubMed ID: 18499888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody pharmacokinetics and pharmacodynamics.
    Wang W; Wang EQ; Balthasar JP
    Clin Pharmacol Ther; 2008 Nov; 84(5):548-58. PubMed ID: 18784655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
    Liu SN; Li C
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.